GlassScriptPhysician profile
Michelle Mathews
NPI 1902101355
$992.18
in general payments reported to CMS, 2019-2025
17 companies · $58.85 in 2025
The $58.85 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $291 · 2023: $321 · 2024: $126 · 2025: $58.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $268.50 | 2021-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $149.56 | 2021-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $126.95 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.26 | 2023-2024 | Xifaxan |
| Mylan Specialty L.P. | $61.69 | 2021-2022 | |
| Amgen INC. | $45.32 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $41.99 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $41.86 | 2021 | |
| Lilly USA, LLC | $31.30 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Organon LLC | $23.67 | 2023 | Nexplanon |
| Axsome Therapeutics, INC. | $20.49 | 2023 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $19.01 | 2023 | Farxiga |
| Daiichi Sankyo INC. | $17.53 | 2023 | Injectafer |
| Abbvie INC. | $14.45 | 2024 | |
| Merck Sharp & Dohme LLC | $13.96 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $12.97 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.